Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Voluntarily Recalls Bestcall IM Inj. 0.5 g
January 5, 2012
- Arena Submits Response to FDA CRL for Lorcaserin: Eisai
January 5, 2012
- CanBas’ CBP501 Receives Orphan Drug Designation from US FDA
January 5, 2012
- SymBio Initiates PII Trials for Relapsed, Refractory Multiple Myeloma Treatment SyB L-0501
December 28, 2011
- Nippon Kayaku Starts Clinical Study for Remicade Biosimilar
December 28, 2011
- Sanofi-aventis Completes Patient Enrollment for Int’l ATLAS Study for Lantus
December 28, 2011
- 2 ARB/CCB Combination Products Enter Top 100 Sales Ranking in 1st Half of FY2011
December 28, 2011
- Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
- Ain Pharmaciez’s Generic Drug Wholesale Subsidiary Showing Steady Growth
December 28, 2011
- Fuji Pharma, Mochida Apply for Japan’s 1st G-CSF Biosimilar
December 27, 2011
- Nippon Kayaku: Pharm Sales Remains Virtually Unchanged in Jun-Nov
December 27, 2011
- Novartis Receives Add’l Approval for Afinitor as 1st pNET Indication in Japan
December 27, 2011
- Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
- Sawai Pharmaceutical Wins Ebastine Patent Dispute
December 26, 2011
- JT to Introduce Anti-HIV Drug Booster from US Company
December 26, 2011
- Toray, JT, Torii Terminate Joint Development of Additional Indication for Nalfurafine
December 26, 2011
- Pfizer Files NDA for Intestinal Amebiasis Treatment Paromomycin in Japan
December 26, 2011
- Novo Nordisk Pharma Submits NDA for Insulin Degludec
December 26, 2011
- Takeda to Set Up New Unit to Support Investigator-Initiated Research
December 22, 2011
- BMKK, Pfizer Japan Apply for Apixaban for SPAF in Japan
December 22, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…